Clinical Trial: Evaluation of the Efficacy of Streptococcus Salivarius Evol12(R) in the Reduction of Recurrent Adenotonsillitis in Children

U.S., Nov. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07235826) titled 'Evaluation of the Efficacy of Streptococcus Salivarius Evol12(R) in the Reduction of Recurrent Adenotonsillitis in Children' on Nov. 14.

Brief Summary: This prospective, multicenter, randomized, double-blind, placebo-controlled, cross-over clinical trial will evaluate the efficacy and safety of Streptococcus salivarius Evol12(R) (Bactoblis(R) Evol) in reducing the recurrence and duration of acute febrile adenotonsillitis in children aged 3 to 11 years. Participants will receive either the probiotic or a matching placebo for 3 months, followed by a 7-day wash-out and a second 3-month treatment period with the alternative product. The...